Pharmicell Co., Ltd. (005690.KS)
KRW 8000.0
(0.63%)
KRW 8000.0
(0.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8.44 Billion KRW | -72.29% |
| 2022 | 8.9 Billion KRW | 17.7% |
| 2021 | 12.86 Billion KRW | 49.58% |
| 2020 | 7.09 Billion KRW | 77.12% |
| 2019 | 4.24 Billion KRW | 106.1% |
| 2018 | -11 Billion KRW | -93.6% |
| 2017 | -1.23 Billion KRW | 1068.12% |
| 2016 | 2.85 Billion KRW | 184.89% |
| 2015 | -3.35 Billion KRW | 63.28% |
| 2014 | -25.06 Billion KRW | -109.94% |
| 2013 | -20.14 Billion KRW | 63.38% |
| 2012 | -11.91 Billion KRW | 16.57% |
| 2011 | -15.43 Billion KRW | -15.87% |
| 2010 | -12.39 Billion KRW | -382.04% |
| 2009 | -3 Billion KRW | -30.27% |
| 2008 | -1.88 Billion KRW | -541.13% |
| 2007 | 159 Million KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.31 Billion KRW | -140.21% |
| 2024 Q2 | 2.97 Billion KRW | 385.81% |
| 2023 Q4 | 618.77 Million KRW | -49.31% |
| 2023 FY | - KRW | -72.29% |
| 2023 Q1 | 3.89 Billion KRW | 274.85% |
| 2023 Q2 | 1.28 Billion KRW | -67.05% |
| 2023 Q3 | 1.22 Billion KRW | -4.86% |
| 2022 Q1 | 6.14 Billion KRW | 373.81% |
| 2022 Q2 | 1.96 Billion KRW | -67.97% |
| 2022 Q4 | -2.22 Billion KRW | -161.79% |
| 2022 Q3 | 3.6 Billion KRW | 83.15% |
| 2022 FY | - KRW | 17.7% |
| 2021 Q1 | 2.62 Billion KRW | 315.47% |
| 2021 Q3 | 5.08 Billion KRW | 93.46% |
| 2021 Q4 | 1.29 Billion KRW | -74.49% |
| 2021 Q2 | 2.62 Billion KRW | 0.26% |
| 2021 FY | - KRW | 49.58% |
| 2020 FY | - KRW | 77.12% |
| 2020 Q3 | 1.41 Billion KRW | -65.9% |
| 2020 Q2 | 4.15 Billion KRW | 165.77% |
| 2020 Q4 | 630.72 Million KRW | -55.53% |
| 2020 Q1 | 1.56 Billion KRW | 48.98% |
| 2019 Q4 | 1.05 Billion KRW | 338.93% |
| 2019 FY | - KRW | 106.1% |
| 2019 Q1 | 1.39 Billion KRW | -34.64% |
| 2019 Q2 | 1.65 Billion KRW | 18.42% |
| 2019 Q3 | 239.31 Million KRW | -85.51% |
| 2018 FY | - KRW | -93.6% |
| 2018 Q3 | 221.78 Million KRW | 5004.67% |
| 2018 Q2 | -4.52 Million KRW | 98.23% |
| 2018 Q1 | -255.43 Million KRW | -100.75% |
| 2018 Q4 | 2.13 Billion KRW | 862.09% |
| 2017 FY | - KRW | 1068.12% |
| 2017 Q2 | -885.91 Million KRW | -1142.82% |
| 2017 Q4 | 34.05 Billion KRW | 21125.85% |
| 2017 Q3 | 160.46 Million KRW | 118.11% |
| 2017 Q1 | -71.28 Million KRW | -114.6% |
| 2016 Q1 | 436.8 Million KRW | 136.2% |
| 2016 Q3 | 1.55 Billion KRW | 325.68% |
| 2016 FY | - KRW | 184.89% |
| 2016 Q2 | 365.7 Million KRW | -16.28% |
| 2016 Q4 | 488.29 Million KRW | -68.63% |
| 2015 Q2 | -353.69 Million KRW | 68.06% |
| 2015 Q4 | -1.2 Billion KRW | -75.75% |
| 2015 FY | - KRW | 63.28% |
| 2015 Q1 | -1.1 Billion KRW | 73.35% |
| 2015 Q3 | -686.54 Million KRW | -94.11% |
| 2014 Q3 | -1.31 Billion KRW | 48.45% |
| 2014 FY | - KRW | -109.94% |
| 2014 Q4 | -4.15 Billion KRW | -216.53% |
| 2014 Q2 | -2.54 Billion KRW | -93.08% |
| 2014 Q1 | -1.31 Billion KRW | 74.29% |
| 2013 Q2 | -1.47 Billion KRW | -13331.23% |
| 2013 FY | - KRW | 63.38% |
| 2013 Q4 | -5.12 Billion KRW | -329.22% |
| 2013 Q3 | 2.23 Billion KRW | 252.11% |
| 2013 Q1 | 11.11 Million KRW | 100.24% |
| 2012 Q2 | -2.92 Billion KRW | -24.13% |
| 2012 Q1 | -2.35 Billion KRW | 0.0% |
| 2012 FY | - KRW | 16.57% |
| 2012 Q4 | -4.61 Billion KRW | -151.07% |
| 2012 Q3 | -1.83 Billion KRW | 37.06% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 FY | - KRW | -15.87% |
| 2011 Q3 | -3.99 Billion KRW | -71.68% |
| 2011 Q1 | -1.76 Billion KRW | 65.66% |
| 2011 Q2 | -2.32 Billion KRW | -32.08% |
| 2010 Q2 | -1.74 Billion KRW | -42.16% |
| 2010 Q3 | -4.18 Billion KRW | -139.99% |
| 2010 Q4 | -5.13 Billion KRW | -22.52% |
| 2010 FY | - KRW | -382.04% |
| 2010 Q1 | -1.22 Billion KRW | -428.71% |
| 2009 Q1 | -509.24 Million KRW | -240.56% |
| 2009 Q2 | 410.98 Million KRW | 180.7% |
| 2009 Q3 | -2.82 Billion KRW | -787.32% |
| 2009 Q4 | 373.4 Million KRW | 113.22% |
| 2009 FY | - KRW | -30.27% |
| 2008 Q1 | -396.8 Million KRW | -116.18% |
| 2008 Q4 | 362.3 Million KRW | 115.73% |
| 2008 Q3 | -2.3 Billion KRW | -1759.9% |
| 2008 Q2 | -123.8 Million KRW | 68.8% |
| 2008 FY | - KRW | -541.13% |
| 2007 Q3 | -35.65 Million KRW | -108.41% |
| 2007 Q1 | 239.18 Million KRW | 0.0% |
| 2007 Q2 | 423.67 Million KRW | 77.13% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | -183.55 Million KRW | -414.85% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ORIENT BIO Inc. | 15.66 Billion KRW | 46.127% |
| Green Cross Holdings Corporation | 66.84 Billion KRW | 87.373% |
| Green Cross Holdings Corporation | 109.81 Billion KRW | 92.314% |
| Green Cross Corporation | 109.81 Billion KRW | 92.314% |
| GeneOne Life Science, Inc. | -63.69 Billion KRW | 113.25% |
| Celltrion, Inc. | 897.26 Billion KRW | 99.059% |
| Samsung Biologics Co.,Ltd. | 1603.46 Billion KRW | 99.474% |
| SK bioscience Co.,Ltd. | 22.77 Billion KRW | 62.943% |
| SK Biopharmaceuticals Co., Ltd. | -22.2 Billion KRW | 138.011% |
| Prestige BioPharma Limited | -31.04 Billion KRW | 127.185% |